TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01615796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
Study: NCT04345406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEIs
Description: Captopril or enalapril

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: alexoquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: alexoquine
Study: NCT01354041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
Study: NCT03532581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given Subcutaneous injection
Study: NCT05104294

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography- Angiography
Description: Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Photopic negative response
Description: Both the implicit time and amplitude of PhNR were recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Photopic negative response
Description: Both the implicit time and amplitude of PhNR were recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Photopic negative response
Description: Both the implicit time and amplitude of PhNR were recorded.
Study: NCT00011986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT03343613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: PD-L1 inhibitor administered IV
Study: NCT03532581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: Undergo lymphangiography
Study: NCT02952703

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief pre-delivery smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: additional pre-delivery smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post- delivery smoking cessation counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentives
Study: NCT03372668

Intervention type: OTHER
Group type: OTHER
Intervention: massage therapy combined with components of mirror therapy
Description: Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb.
Study: NCT01807260

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave lithotripsy
Description: All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave lithotripsy
Description: All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
Study: NCT01106742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AndoSan
Description: AndoSan, 20mlx3, 12 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AndoSan
Description: AndoSan, 20mlx3, 12 days
Study: NCT02539355

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet A
Description: 12-week diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet B
Description: 12-week Diet
Study: NCT03933514

Intervention type: OTHER
Intervention: Plaque control
Description: Children were instructed about the hygiene procedures

Intervention type: OTHER
Intervention: Plaque control
Description: Children were instructed about the hygiene procedures
Study: NCT00664950

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: surgical repair of hip fracture using conventional sliding hip screw

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IntertAn IM nail
Description: interTAN IM nail
Study: NCT03737045

Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
Study: NCT03749798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Intraoperative wavefront measurements will be carried out during cataract surgery
Study: NCT00485589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study: NCT02155361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Citrullus colocynthis fruit oil (1%)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical vehicle oil
Study: NCT03106948

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cuprimine Oral Product
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
Study: NCT04043403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Loop DBS
Description: Standard DBS therapy at a constant frequency and voltage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open Loop DBS
Description: Standard DBS therapy at a constant frequency and voltage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive (Closed Loop) DBS
Description: DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive (Closed Loop) DBS
Description: DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state
Study: NCT03387956

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal atropine
Description: 100ug intrathecal atropine will be injected with spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal atropine
Description: 100ug intrathecal atropine will be injected with spinal anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: intravenous 8 mg dexamethasone (2ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: intravenous 8 mg dexamethasone (2ml).
Study: NCT04043403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Open Loop DBS
Description: Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.
Study: NCT03054987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-BD
Description: EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
Study: NCT00980785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 5 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT02433860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmacist nicotine cessation counseling using SCRIPT protocol
Description: Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately \> 36 weeks gestation or at delivery.
Study: NCT00658710

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy sessions
Description: two physical therapy sessions per week for two months
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02677181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: rabbit ATG（Sanofi）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Description: cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02677181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: short-term methotrexate
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study: NCT02677181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: short-term methotrexate
Study: NCT03574922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercises
Description: Balance Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercises
Description: Balance Exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization exercises
Description: Core Stabilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization exercises
Description: Core Stabilization exercises
Study: NCT05017259

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calorie restriction diet
Description: The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calorie restriction diet
Description: The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
Study: NCT04636242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
Study: NCT01061736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment
Study: NCT00011986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study: NCT01061736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment
Study: NCT03594110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Taken daily with or without food
Study: NCT04636242

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin Biopsy
Description: A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Aminolevulinic Acid + Phototherapy
Description: 5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
Study: NCT04583020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 60Gy/30

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
Study: NCT02033330

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phenolics form orange peel

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phenolics form orange peel

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phenolics form orange peel
Study: NCT03594110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Taken daily with or without food
Study: NCT02063451

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very Low Calorie Diet (VLCD)
Description: Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
Study: NCT02332928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Study: NCT04578626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The use of filiform needles to stimulate muscles and connective tissues. The needle is inserted in a direction perpendicular to the skin, a local twitch response is looked for and, once found, the needle is kept in the muscle without moving for 10 seconds. No substances are injected.
Study: NCT01015521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoflavone Prodrug
Description: Aminoflavone Prodrug administered D1, D8 of 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminoflavone Prodrug
Description: Aminoflavone Prodrug administered D1, D8 of 21-day cycle
Study: NCT02996396

Intervention type: DEVICE
Intervention: Nellix Endovascular Aneurysm Sealing System (Nellix®-System)
Description: The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
Study: NCT02194790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Integrated CKD Care
Description: Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
Study: NCT03237806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep sedated
Description: Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light sedated
Description: Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
Study: NCT01334554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: 20 mg three times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active drug